Marinus Pharma Analyst Ratings
Marinus Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/08/2023 | 261.79% | Truist Securities | $32 → $25 | Maintains | Buy |
09/21/2023 | 305.21% | Cantor Fitzgerald | → $28 | Reiterates | Overweight → Overweight |
09/20/2023 | 203.91% | RBC Capital | $20 → $21 | Maintains | Outperform |
09/20/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
08/11/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
08/11/2023 | 189.44% | RBC Capital | $21 → $20 | Maintains | Outperform |
08/11/2023 | 363.1% | Truist Securities | $42 → $32 | Maintains | Buy |
08/11/2023 | 88.13% | Ladenburg Thalmann | $17 → $13 | Maintains | Buy |
08/11/2023 | 189.44% | Baird | $24 → $20 | Maintains | Outperform |
08/11/2023 | 102.6% | Oppenheimer | → $14 | Downgrades | Outperform → Perform |
06/23/2023 | 305.21% | Cantor Fitzgerald | $28 → $28 | Reiterates | Overweight → Overweight |
06/14/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
05/30/2023 | 160.49% | JMP Securities | → $18 | Reiterates | Market Outperform → Market Outperform |
05/12/2023 | 507.81% | Truist Securities | $50 → $42 | Maintains | Buy |
05/12/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | Buy → Buy |
04/25/2023 | 218.38% | RBC Capital | → $22 | Reiterates | → Outperform |
04/25/2023 | 102.6% | Oppenheimer | $12 → $14 | Maintains | Outperform |
03/08/2023 | 305.21% | Cantor Fitzgerald | → $28 | Reiterates | → Overweight |
03/08/2023 | 218.38% | RBC Capital | $23 → $22 | Maintains | Outperform |
03/08/2023 | 160.49% | JMP Securities | $19 → $18 | Maintains | Market Outperform |
03/08/2023 | 290.74% | HC Wainwright & Co. | → $27 | Reiterates | → Buy |
01/23/2023 | 232.85% | SVB Leerink | $27 → $23 | Maintains | Outperform |
01/20/2023 | 232.85% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
11/09/2022 | 247.32% | Baird | $32 → $24 | Maintains | Outperform |
03/22/2022 | 623.59% | Truist Securities | $35 → $50 | Maintains | Buy |
03/22/2022 | 218.38% | JMP Securities | $21 → $22 | Maintains | Market Outperform |
03/22/2022 | 290.74% | SVB Leerink | $30 → $27 | Maintains | Outperform |
12/20/2021 | 334.15% | SVB Leerink | $32 → $30 | Maintains | Outperform |
09/30/2020 | 406.51% | Truist Securities | → $35 | Initiates Coverage On | → Buy |
09/28/2020 | 406.51% | HC Wainwright & Co. | $9 → $35 | Maintains | Buy |
09/15/2020 | 15.77% | SVB Leerink | $6 → $8 | Maintains | Outperform |
07/01/2020 | 30.25% | HC Wainwright & Co. | $6 → $9 | Maintains | Buy |
07/01/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
05/05/2020 | -13.17% | Cantor Fitzgerald | $7 → $6 | Reiterates | → Overweight |
01/10/2020 | -13.17% | HC Wainwright & Co. | $5 → $6 | Reiterates | → Buy |
12/20/2019 | -13.17% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
10/18/2019 | 1.3% | Cantor Fitzgerald | → $7 | Assumes | → Overweight |
09/03/2019 | -27.64% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
03/05/2019 | 44.72% | Jefferies | → $10 | Initiates Coverage On | → Buy |
02/27/2019 | -27.64% | Mizuho | $13 → $5 | Downgrades | Buy → Neutral |
02/06/2019 | 44.72% | Leerink Swann | → $10 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/08/2023 | 261.79% | Truist 證券 | 32 美元 → 25 美元 | 維護 | 購買 |
09/21/2023 | 305.21% | 坎託·菲茨傑拉德 | → 28 美元 | 重申 | 超重 → 超重 |
09/20/2023 | 203.91% | 加拿大皇家銀行資本 | 20 美元 → 21 美元 | 維護 | 跑贏大盤 |
09/20/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 購買 → 購買 |
08/11/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 購買 → 購買 |
08/11/2023 | 189.44% | 加拿大皇家銀行資本 | 21 美元 → 20 美元 | 維護 | 跑贏大盤 |
08/11/2023 | 363.1% | Truist 證券 | 42 美元 → 32 美元 | 維護 | 購買 |
08/11/2023 | 88.13% | 拉登堡塔爾曼 | 17 美元 → 13 美元 | 維護 | 購買 |
08/11/2023 | 189.44% | 貝爾德 | 24 美元 → 20 美元 | 維護 | 跑贏大盤 |
08/11/2023 | 102.6% | 奧本海默 | → 14 美元 | 降級 | 跑贏大盤 → 表現 |
06/23/2023 | 305.21% | 坎託·菲茨傑拉德 | 28 美元 → 28 美元 | 重申 | 超重 → 超重 |
06/14/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 購買 → 購買 |
05/30/2023 | 160.49% | JMP 證券 | → 18 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
05/12/2023 | 507.81% | Truist 證券 | 50 美元 → 42 美元 | 維護 | 購買 |
05/12/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | 購買 → 購買 |
2023 年 4 月 25 日 | 218.38% | 加拿大皇家銀行資本 | → 22 美元 | 重申 | → 跑贏大盤 |
2023 年 4 月 25 日 | 102.6% | 奧本海默 | 12 美元 → 14 美元 | 維護 | 跑贏大盤 |
03/08/2023 | 305.21% | 坎託·菲茨傑拉德 | → 28 美元 | 重申 | → 超重 |
03/08/2023 | 218.38% | 加拿大皇家銀行資本 | 23 美元 → 22 美元 | 維護 | 跑贏大盤 |
03/08/2023 | 160.49% | JMP 證券 | 19 美元 → 18 美元 | 維護 | 市場表現跑贏大盤 |
03/08/2023 | 290.74% | HC Wainwright & Co. | → 27 美元 | 重申 | → 購買 |
2023 年 1 月 23 日 | 232.85% | SVB Leerink | 27 美元 → 23 美元 | 維護 | 跑贏大盤 |
01/20/2023 | 232.85% | 加拿大皇家銀行資本 | → 23 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
11/09/2022 | 247.32% | 貝爾德 | 32 美元 → 24 美元 | 維護 | 跑贏大盤 |
03/22/2022 | 623.59% | Truist 證券 | 35 美元 → 50 美元 | 維護 | 購買 |
03/22/2022 | 218.38% | JMP 證券 | 21 美元 → 22 美元 | 維護 | 市場表現跑贏大盤 |
03/22/2022 | 290.74% | SVB Leerink | 30 美元 → 27 美元 | 維護 | 跑贏大盤 |
2021 年 12 月 20 日 | 334.15% | SVB Leerink | 32 美元 → 30 美元 | 維護 | 跑贏大盤 |
09/30/2020 | 406.51% | Truist 證券 | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
09/28/2020 | 406.51% | HC Wainwright & Co. | 9 美元 → 35 美元 | 維護 | 購買 |
2020 年 9 月 15 日 | 15.77% | SVB Leerink | 6 美元 → 8 美元 | 維護 | 跑贏大盤 |
07/01/2020 | 30.25% | HC Wainwright & Co. | 6 美元 → 9 美元 | 維護 | 購買 |
07/01/2020 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
05/05/2020 | -13.17% | 坎託·菲茨傑拉德 | 7 美元 → 6 美元 | 重申 | → 超重 |
2020 年 10 月 1 日 | -13.17% | HC Wainwright & Co. | 5 美元 → 6 美元 | 重申 | → 購買 |
12/20/2019 | -13.17% | 奧本海默 | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
10/18/2019 | 1.3% | 坎託·菲茨傑拉德 | → 7 美元 | 假設 | → 超重 |
2019 年 3 月 9 日 | -27.64% | HC Wainwright & Co. | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2019 年 5 月 3 日 | 44.72% | 傑富瑞集團 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
02/27/2019 | -27.64% | 瑞穗市 | 13 美元 → 5 美元 | 降級 | 買入 → 中性 |
02/06/2019 | 44.72% | Leerink Swann | → 10 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Marinus Pharma (MRNS)?
Marinus Pharma(MRNS)的目標價格是多少?
The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by Truist Securities on November 8, 2023. The analyst firm set a price target for $25.00 expecting MRNS to rise to within 12 months (a possible 261.79% upside). 24 analyst firms have reported ratings in the last year.
Truist Securities於2023年11月8日公佈了Marinus Pharma(納斯達克股票代碼:MRNS)的最新目標股價。該分析公司將目標股價定爲25.00美元,預計MRNS將在12個月內上漲至25.00美元(可能上漲261.79%)。去年有24家分析公司公佈了評級。
What is the most recent analyst rating for Marinus Pharma (MRNS)?
Marinus Pharma(MRNS)的最新分析師評級是多少?
The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by Truist Securities, and Marinus Pharma maintained their buy rating.
Marinus Pharma(納斯達克股票代碼:MRNS)的最新分析師評級由Truist Securities提供,Marinus Pharma維持其買入評級。
When is the next analyst rating going to be posted or updated for Marinus Pharma (MRNS)?
Marinus Pharma(MRNS)的下一個分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Marinus Pharma的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。Marinus Pharma的最後一次評級是在2023年11月8日公佈的,因此您應該預計下一個評級將在2024年11月8日左右公佈。
Is the Analyst Rating Marinus Pharma (MRNS) correct?
分析師對Marinus Pharma(MRNS)的評級是否正確?
While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a maintained with a price target of $32.00 to $25.00. The current price Marinus Pharma (MRNS) is trading at is $6.91, which is out of the analyst's predicted range.
儘管評級是主觀的,並將發生變化,但最新的Marinus Pharma(MRNS)評級維持不變,目標股價爲32.00美元至25.00美元。Marinus Pharma(MRNS)目前的交易價格爲6.91美元,超出了分析師的預期區間。